Dongwha Pharm.Co.Ltd (000020) - Total Liabilities
Based on the latest financial reports, Dongwha Pharm.Co.Ltd (000020) has total liabilities worth ₩238.27 Billion KRW (≈ $161.48 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Dongwha Pharm.Co.Ltd (000020) net asset momentum to track the company's year-over-year net asset growth rate.
Dongwha Pharm.Co.Ltd - Total Liabilities Trend (2011–2025)
This chart illustrates how Dongwha Pharm.Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. See Dongwha Pharm.Co.Ltd (000020) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Dongwha Pharm.Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Dongwha Pharm.Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UVAT Technology Co Ltd
TWO:3580
|
Taiwan | NT$690.32 Million |
|
Martin Midstream Partners LP
NASDAQ:MMLP
|
USA | $592.86 Million |
|
Loop Telecommunication International Inc
TW:3025
|
Taiwan | NT$399.52 Million |
|
Yoosung T&S Co. Ltd
KQ:024800
|
Korea | ₩99.40 Billion |
|
Forsys Metals Corp.
TO:FSY
|
Canada | CA$358.54K |
|
Nerdy Inc
NYSE:NRDY
|
USA | $44.04 Million |
|
Pelican Acquisition Corporation Ordinary Shares
NASDAQ:PELI
|
USA | $583.17K |
|
Data Communications Management Ltd
TO:DCM
|
Canada | CA$321.00 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Dongwha Pharm.Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 000020 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dongwha Pharm.Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dongwha Pharm.Co.Ltd (2011–2025)
The table below shows the annual total liabilities of Dongwha Pharm.Co.Ltd from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩240.73 Billion ≈ $163.14 Million |
+10.45% |
| 2024-12-31 | ₩217.96 Billion ≈ $147.71 Million |
+38.02% |
| 2023-12-31 | ₩157.92 Billion ≈ $107.02 Million |
+91.50% |
| 2022-12-31 | ₩82.46 Billion ≈ $55.88 Million |
-5.94% |
| 2021-12-31 | ₩87.67 Billion ≈ $59.41 Million |
-3.79% |
| 2020-12-31 | ₩91.13 Billion ≈ $61.75 Million |
+21.25% |
| 2019-12-31 | ₩75.15 Billion ≈ $50.93 Million |
+2.67% |
| 2018-12-31 | ₩73.20 Billion ≈ $49.61 Million |
+4.15% |
| 2017-12-31 | ₩70.28 Billion ≈ $47.63 Million |
-1.95% |
| 2016-12-31 | ₩71.68 Billion ≈ $48.58 Million |
-17.68% |
| 2015-12-31 | ₩87.07 Billion ≈ $59.01 Million |
+4.47% |
| 2014-12-31 | ₩83.35 Billion ≈ $56.48 Million |
-6.28% |
| 2013-12-31 | ₩88.93 Billion ≈ $60.27 Million |
-8.59% |
| 2012-12-31 | ₩97.29 Billion ≈ $65.93 Million |
-11.40% |
| 2011-12-31 | ₩109.81 Billion ≈ $74.42 Million |
-- |
About Dongwha Pharm.Co.Ltd
Dongwha Pharm.Co.,Ltd manufactures and sells pharmaceutical products in South Korea. It offers ethical products in the areas of alimentary system, antibiotic, cardiovascular/metabolic disease, NSAID/respiratory system, muscle relaxants/musculoskeletal system, nervous system, and dermatological/urinary system; OTC products in the areas of alimentary system, cold remedy, NSAID/respiratory system, d… Read more